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Abstract
Most people living with HIV (PLHIV) with reliable access to antiretroviral treatment (ART)
have a life expectancy similar to uninfected populations. Despite this, HIV can negatively
affect their social and psychological wellbeing. This study aimed to enhance understanding
of the expectations PLHIV hold for HIV cure research and the implications this has for HIV
cure research trials. We interviewed 20 Australian PLHIV about their expectations for HIV
cure research outcomes and the impact a potential cure for HIV may have on their everyday
lives. Data were analysed thematically, using both inductive and deductive approaches. The
significance of a cure for HIV was expressed by participants as something that would offer
relief from their sense of vigilance or uncertainty about their health into the future. A cure
was also defined in social terms, as alleviation from worry about potential for onward HIV
transmission, concerns for friends and family, and the negative impact of HIV-related
stigma. Participants did not consider sustained medication-free viral suppression (or remis-
sion) as a cure for HIV because this did not offer certainty in remaining virus free in a way
that would alleviate these fears and concerns. A cure was seen as complete elimination of
HIV from the body. There is an ethical need to consider the expectations of PLHIV in design
of, and recruitment for, HIV cure-related research. The language used to describe HIV cure
research should differentiate the long-term aspiration of achieving complete elimination of
HIV from the body and possible shorter-term therapeutic advances, such as achieving medi-
cation free viral suppression.
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Introduction
Antiretroviral treatment (ART) has significantly reduced morbidity and mortality among peo-
ple living with HIV (PLHIV) to the point where, with consistent access to and use of ART,
they may assume a life expectancy similar to uninfected populations [1] and HIV is now often
considered a chronic illness. Furthermore, several large studies provide evidence that there is
no risk of sexual transmission of HIV to others from PLHIV whose virus is supressed, summa-
rised by the expression now used widely in HIV prevention, treatment uptake and anti-stigma
campaigns, undetectable = untransmittable [2, 3], and pre-exposure prophylaxis medication
provides reliable options for prevention of HIV infection [4]. The lower disease burden has
lessened the impact of HIV on affected communities with consistent access to ART. However,
globally, fewer than half of all PLHIV have reliable access to ART because of major financial,
logistical, cultural and political barriers to ART scale-up [5]. In addition, while ART improves
immune function, it may not reverse existing negative health effects related to HIV infection.
Toxicities associated with long-term ART may also have a negative impact on health [1]. For
these reasons, a cure for HIV is still considered clinically and strategically important [1].
In recent years, there has been a growing momentum in scientific research toward finding a
cure for HIV infection. This has been supported by the International AIDS Society’s ‘Towards
a Cure Initiative’ and other international networks focused on HIV cure research [6]. Globally,
there are a number of early stage (phase I/II) clinical trials exploring potential pathways to
achieve a cure for HIV. The risks and benefits of being involved in these trials have been well
documented, showing that some trials present a risk to the health of PLHIV who participate
due to interruption of ART for research purposes [7]. Despite this, recent studies have indi-
cated PLHIV in high-income countries, including the United Kingdom, United States, Thai-
land and Australia, are likely to be motivated to participate in HIV cure research for altruistic
reasons, including a desire to help future generations and/or to advance science [8–11].
A small number of studies have explored the expectations of PLHIV for the longer-term
outcomes of HIV cure research [12]. In particular, studies have focused on what PLHIV per-
ceive to be the most desired outcomes associated with an HIV cure. For example, a study of
PLHIV in the Netherlands found the most highly desired outcomes of a cure were: alleviating
uncertainty about future health problems; reducing the negative social impact of HIV associ-
ated with stigma; and no longer being concerned about onward HIV transmission [13]. Simi-
lar results have been found in British and Australian studies [9, 14]. These studies highlight
complexity in the way ‘HIV cure’ is defined. A cure for HIV has often been used in reference
to long-term, medication-free, viral suppression (also called HIV ‘control’ or ‘remission’) [15],
as well as a cure in which HIV is eliminated from the body (sometimes referred to as a ‘steriliz-
ing’ cure) [16, 17]. These outcomes could be quite different with respect to whether PLHIV
consider themselves to be cured of HIV or not, particularly if they are looking to achieve long-
term certainty about their health and inability to transmit HIV, or if a cure is defined as being
HIV antibody negative. Understanding the perspectives of PLHIV on HIV cure outcomes
sheds light on assumptions about, and desires for, HIV cure research held by populations who
are most affected by HIV and who are likely to be involved in future observational and inter-
ventional clinical trials [12, 18].
This paper reports findings from a research project in which Australian PLHIV were inter-
viewed about issues likely to influence their willingness to participate in clinical trials related
to HIV cure research, including the perceived impact that a cure for HIV would have on their
lives. Here, we present findings focused on the personal significance of a potential HIV cure to
study participants and the way that this influenced their perceptions of HIV cure research.
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This analysis follows on from our previous report of findings from this study on willingness to
participate in HIV cure trials in Australia [11].
Materials and method
The study involved one-to-one, in-depth interviews investigating the different ways PLHIV
think about a possible cure and how they might consider participation in cure-related trials.
Qualitative interviews such as these are highly suited to revealing values, experiences, expecta-
tions and ideas explored interactively and conversationally.
Recruitment
The study inclusion criteria were: living with HIV; aged over 18 years; and living in Australia.
The study utilised purposive sampling, whereby participants were recruited through advertis-
ing distributed by HIV community organisations, HIV clinics and relevant online social net-
works. The advertisements invited PLHIV to contact the researchers if they were willing to be
interviewed about the social and ethical implications of HIV cure research. Prior to the inter-
view, researchers (AW and JP) had informal conversations with each participant to ensure any
questions they had about the study or the researchers could be answered and to get a sense of
any potential vulnerabilities or concerns. All participants were provided with information
about professional and peer support services in their local area for PLHIV. Ethics approval for
this study was granted by the La Trobe University College of Science, Health and Engineering
Human Ethics Committee (S15-152).
Data collection
Twenty PLHIV were interviewed in 2016. Interviews took approximately one hour and were
conducted either via telephone or face to face. Interviews were conducted by two of the
researchers (AW and JP). Oral consent to participate was obtained from all participants prior
to the interview and with a signed consent form. No compensation was provided for participa-
tion. Interviewees were informed that the interviewers were researchers who had prior experi-
ence working in HIV social research and the study was in no way connected to clinical
research toward a cure for HIV.
Interviews followed a semi-structured guide (Table 1) that explored issues or queries that
had been raised at a community forum on HIV cure research for PLHIV and PLHIV advocacy
groups held in Melbourne, Australia, in February 2016 [19]. The interview guide was designed
to explore participants’ general knowledge of, and assumptions about, HIV cure research and
their attitudes toward participation in related clinical trials. Interviewers used prompts and
probing statements to encourage participants to expand on the topics raised in each question
[20]. Participants were also presented with short vignettes (Table 1) that posed hypothetical
scenarios relating to participation in HIV cure clinical trials in which the risks and benefits of
participation were described. The use of vignettes was intended to encourage participants to
reflect on possible points of tension or contradictions in their thinking about the risks and
benefits of participation in HIV cure research [21]. In the final section of the interview, partici-
pants were asked to explain how they interpreted a set of ‘closed’ questions on willingness to
participate in HIV cure research trials (Table 1). The original aim of this was to validate these
questions for use for future quantitative survey research. However, we found that participants’
responses to these questions contained rich information on their perceptions of what a cure
for HIV would mean for their lives. As such, we included responses to these interview ques-
tions in the dataset for the current analysis.
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Data analysis
The interviews were transcribed verbatim and participants had the option of reviewing their
transcript to edit or remove any details. They were also able to withdraw their consent to par-
ticipate after viewing their transcript, although no participants chose to do this. One researcher
(AW) verified the transcripts for accuracy and removed identifying details. Two researchers
(AW and JP) independently conducted a thematic analysis. Data were initially coded to
explore pre-determined themes: perceptions of HIV cure, and willingness to participate in
Table 1. Interview guide.
General questions 1. When you were coming in to do this interview today, was there anything you were thinking or wondering about in relation to
the topic of the interview that you can share with me?
2. Do you think that a cure for HIV will become available in your lifetime? (Why/why not?)
3. Have you ever deliberately searched for information about HIV cure? (eg. Googled, asked doctors?) Can you tell me more
about why you were searching?
4. Can you tell me what you know, if anything, about recent research aimed at developing an HIV cure?
a. Do you recall where you found this information?
b. How do you feel about this recent research?
c. How do you think other PLHIV feel about this research?
5. Are there circumstances in which you would consider participating in a clinical trial relating to HIV cure research? (Why/why
not?)
6. What do you imagine this type of clinical trial might involve?
7. Do you imagine such a trial might involve risks to your health? What sort of risks? What level of risk would you be willing to
take?
8. What would have to happen for you to consider yourself cured of HIV?
9. How do you feel about the following cure scenarios:
a. You no longer need to take HIV medication, and you cannot pass the virus on to others, but you could potentially get HIV
again (you have no natural immunity).
b. You still have HIV, but you do not need to take daily medication to maintain viral suppression.
c. Your viral load is undetectable and you no longer need medication to maintain viral suppression, but doctors are unsure if
your HIV will rebound. You will need regular blood tests to monitor viral load for at least the next 5–10 years.
10. If a cure for HIV were to become available, how would it change your life?
Hypothetical scenarios posed 1. A clinical trial requires you to go off your antiretroviral medication which means your viral load may be unpredictable for up
to one year. The trial is unlikely to provide any personal benefit to you but may help develop scientific understanding that
could eventually lead to a cure for HIV. Would you be willing to participate in this trial? Why/why not? What, if any, are your
major concerns?
2. A clinical trial will involve taking extra medication on top of your antiretroviral medication for a period of two weeks. The
impact of this new medication on your viral load is unknown and there may be some side effects. Would you be willing to
participate in this trial? Why/why not? What, if any, would be your major concerns?
Interpretation of questions
(interviewees were asked to tell us
what they perceived to be the main
information each question was
seeking to elicit)
• If you had the opportunity to participate in an HIV cure-related clinical trial beginning tomorrow, how willing would you be
to participate? (Not at all willing; somewhat unwilling; somewhat willing; very willing)
If you indicated you are willing, to what extent would the following affect your willingness to participate? (Decrease willingness,
no effect on willingness, increase willingness)
1. If participation would increase scientific understanding of a potential HIV cure but bring no benefit to your health
2. If participation would help future generations find a cure for HIV but bring no benefit to your own health
3. If participation would allow you to go off medication for a short period and still maintain viral suppression
4. If participation would give you access to specialist HIV medical care as part of the trial
5. If you were guaranteed access to medical care for the rest of your life if participation had a negative effect on your health
6. If participation may result in your viral load increasing or being less predictable for up to one year
7. If participation meant you may develop resistance to your current antiretroviral combination
8. If participation would make you more susceptible to disease and illness
9. If participation would require tissue biopsies or other invasive procedures
10. If participation required weekly visits to a medical clinic for several months
https://doi.org/10.1371/journal.pone.0229733.t001
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clinical trials [22–24]. Following this, inductive thematic analysis was undertaken to identify
emergent themes, organise codes into broader themes, identify sub-themes, and explore com-
plexities or contradictions in the data. Researchers identified core themes by paying attention
to emphasis and repetition in the data. To ensure rigour, a process of constant comparison was
used, whereby researchers routinely cross-checked data in interviews that had previously been
analysed to look for consistency or contradiction with emergent themes [25]. This process was
also intended to achieve theoretical saturation of codes. By interrogating each transcript sev-
eral times, and by re-reading transcripts as the researcher’s ideas or perspective developed in
response to subsequent transcripts, each researcher aimed to ensure there were no codes that
were missed or ignored [26]. We do not, however, claim that full data saturation was achieved
with this analysis given that time and budget constraints did not allow for more interviews to
be conducted to further explore themes that had only limited data. Once each researcher had
completed an independent analysis of the data, consistencies and discrepancies in the findings
of each researcher were identified through discussion and collaboratively writing notes and
memos. The coding tree developed through this analysis had broad themes as a base related to
participants’ attitudes toward the possibility of a cure for HIV and toward HIV cure research.
For example, one broad theme was: “Perceptions and expectations for a cure”. Coding nodes
under this included (among others): describing the physical impact of cure, describing the
social impact of cure, anticipating life changes that would come from a cure, minimising the
impact of a cure, wondering about a cure, hoping for a cure, avoiding cure information,
searching for cure information, imagining life without HIV, feeling cynical about a cure, feel-
ing hopeful about a cure, feeling cautious about engaging with cure information, and imaging
cure as relief. These nodes were then further refined to unpack nuance and meaning. For
example, codes under the node “feeling cynical about a cure” included: fearing disappoint-
ment, managing emotions, maintaining a positive attitude toward HIV, mistrusting motives of
big-business, and moving between hope and cynicism. The use of gerunds (words such as feel-
ing, moving, wondering, hoping) in line-by-line coding is a technique recommended by Char-
maz and Belgrave (2012) to assist researchers to move the analysis away from issues or topics
to engage with what participants are doing or feeling [27]. NVivo 12 software was used to orga-
nise the data and manage coding, although this was augmented with manual methods, includ-
ing each researcher reading hardcopies of the transcripts and making notes and highlights
prior to NVivo coding. Memo writing was conducted using standard Word software.
Participant characteristics
Eighteen men and two women were interviewed. The majority of men (n = 16) identified as
‘gay’ or other non-heterosexual identities such as ‘pansexual’ or ‘men who have sex with men’.
This is consistent with the pattern of the Australian HIV epidemic where, in 2016, the majority
of HIV transmissions were among gay or bisexual men of Anglo-Celtic background [28]. The
two women both identified as heterosexual. All participants spoke English fluently, although
one indicated that English was his second language. We did not elicit participants’ cultural and
ethnic backgrounds.
Participant’s ages ranged from 23 to 64 years and the length of time they had been living
with HIV ranged from less than six months to 31 years. Five participants had been living with
HIV for three years or less, three of these for less than six months. Ten participants described
themselves as closely involved in the HIV community sector, either as employees or volunteers
in advocacy and support agencies, or as peer counsellors. Six participants had no contact with
the HIV community sector. In lieu of providing a table listing participant characteristics, we
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have identified the age, gender, sexuality and length of time living with HIV of participants
whose interviews have been quoted in the results section of this paper.
Results
All participants interpreted a cure as being ‘HIV free’, i.e. elimination of HIV from the body.
Being asked about how a cure for HIV would change their lives typically led participants to
reflect on the impact of HIV on their lives to date as a way of identifying the likely social and
psychological benefits of being HIV free. In a separate question, participants were asked about
the acceptability of other possible outcomes of cure research such as sustained viral suppres-
sion or remission. No participants considered these to be a cure for HIV. Rather, a cure was
something that offered certainty that HIV would not return, their viral load would not
rebound, and they could no longer transmit HIV to others. Treatments or interventions that
offered less certainty were seen as welcome advances in HIV treatment, but not as a cure.
Three key themes emerged relating to the meaning and significance this definition of a cure
held for participants: (1) a cure would offer certainty about future health; (2) a cure would mean
an absence of everyday worry; and (3) a cure would be relief from the burden of stigma. Partici-
pants tended to hold both hope and uncertainty about the potential for a cure to be achieved.
A cure offers certainty about future health
Participants were asked what physical, emotional or life changes would need to occur for them
to consider themselves cured of HIV and what impact this would have on their lives. Health,
not surprisingly, was a central theme in most participants’ reflections on the benefits a cure for
HIV would bring to their lives. However, participants did not describe this as an improvement
in their current state of health. Rather, a cure for HIV was seen to offer freedom from anxiety
about future ill health. This was mentioned by participants who had a range of experiences
with HIV, including those who were newly diagnosed and had not experienced ill health asso-
ciated with their infection as well as those living with HIV longer-term.
Well, see, if a cure did become available, oh, it would remove a question I have about my
survivability into the future. It would remove questions that I have about very long-term
maintenance on antiretroviral therapy . . . So, I don’t know–well really, it would be about
removing the questions about what’s going on in the future.
(Male, gay, 54, living with HIV for 25 years)
[Since] becoming HIV positive, I’ve had this general overarching concern of just getting sick,
even though it doesn’t necessarily make much sense, because my viral load is very low and
the agency of the HIV is quite–is pretty minimal in the affairs of my health at the moment.
(Male, gay, 23, living with HIV for four months)
Participants were looking for certainty when it came to a cure; a ‘cure’ that did not guaran-
tee permanent viral suppression or elimination was not considered a cure because it did not
offer relief from anxiety about future ill health, as one participant stated:
[A cure would mean] that I wouldn’t be worried that what if I got a flu or, you know . . . if
you got shingles, or you know something that’s meant one of the other viruses to go a bit
wild, would that set off the HIV again?
(Male, gay, 46, living with HIV for 22 years)
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When questioned about their perceptions of sustained medication-free control of HIV (or
remission) versus elimination of HIV, participants saw long-term control as an advance on
HIV treatment rather than a cure–something that was welcomed and considered important,
but without offering the same level of certainty, as the following participants stated:
Remission is not [a cure]. Cure would be knowing it can’t come back, knowing that any res-
ervoir of HIV would not be reactivated if I ceased medication, that it would be undetectable
as a HIV test in my body, not just undetectable viral load . . . I think that’s my stopping
point around cure. It would have to be confirmed HIV negativity.
(Male, gay, 52, living with HIV for 22 years)
Do you know what that [idea of remission] makes me feel? Cheated, actually. That’s not a
sufficient outcome; it’s a step towards an outcome. You know, I struggle with this as a con-
cept with cancer. They’re in remission. They’re in remission. They’re in remission. And
then the cancer’s gone. In a sense, it screams that we’ve put all the time and money and
research into only getting to second base. It’s not a home run and we need the home run.
We need the home run to push back against the stigma and discrimination, because second
base isn’t going to cut it.
(Male, MSM, 43, living with HIV for 18 years)
Living with HIV was expressed by participants as a state of uncertainty about their future.
While participants did not describe this as something they held consistently at the front of
their minds, questions about what it would feel like to live without HIV evoked responses that
described this sense of uncertainty, vulnerability and vigilance about their health. This sense of
vulnerability was related to the knowledge of HIV being in their body rather than the physical
impact of HIV or of daily ART regimens.
A cure would mean an absence of everyday worry
Participants offered complex answers to questions about the effects a cure for HIV might have
on their lives beyond health. Several participants initially responded by explaining that being
cured of HIV would not have a major impact on their everyday lives apart from not having to
take medication. Then, as participants thought more about the question, they identified poten-
tial social and emotional benefits. The following quotation illustrates this well:
How would [a cure] change my life? It would not change my day-to-day life to be honest
because of the way I live. It would–there is an underlying fear and worry with regards to
my family. My partner is not HIV positive; neither are any of my children. Thank good-
ness. So–and I actually haven’t disclosed to any of my children, just because I’ve been
well, and it hasn’t been necessary–and as they get older, they’ve got so much to deal with
anyway just being children, that we’ve chosen not to tell them. So, in that way, it would
give no relief to them. It would be lovely not to have to take medication every day and to
just have that underlying, you know, that little-voice worry if I get a cold. It still happens,
you know, if something–if I don’t get better within a week, then there’s always that little
worry, that niggling little fear. I know that my mother and father would be very thankful,
and they would–they’re getting older–and they would stop worrying. But day to day, you
know, like, I’m not on any benefits [government financial support], I’m not–I just live
quite a normal life. So, day to day, it wouldn’t affect me, but it would have a huge
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psychological effect on me, I’m sure, and the rest of the people who know me and worry
about me.
(Female, heterosexual, 44, living with HIV for 18 years)
As is also evident in the above quotation, one desired outcome of cure for participants was
relief from worry. In many participants’ responses, HIV was described as creating a psycholog-
ical burden relating to anxiety about health, relationships or social interactions, and fear of
onward transmission of HIV, which people held despite knowledge of the effectiveness of ART
in preventing this.
[With long-term viral suppression] then I could potentially have unprotected sex and not
infect anyone, have kids and, like, all of the research that’s gone into that. But, I know it’s
[HIV] in my DNA, and I know I’m not cured . . . For me, cured is that I don’t have to think
about it. And the quality of the medicine has almost put us to that point. The last step is the
mental.
(Male, gay, 37, living with HIV for four months)
Well, you couldn’t imagine how much [a cure] would change my life. Not being sick isn’t
the only thing. It doesn’t erase my past. It doesn’t erase the knowledge of this virus is unlike
any other type of illness, and it’s like a cloud hanging over you, your whole life.
(Male, heterosexual, 43, living with HIV for 31 years)
[Being] able to pass on [HIV] is a concern as well, that’s the main fact. I guess, when it
comes to my own body, I can live a fairly normal life just taking a pill a day so the biggest
thing for me is being able to pass it on to someone else anyway and so yeah–the cure would
hopefully mean that I am free of it that I wouldn’t have a risk of infecting someone else–
that’s more my own body I guess.
(Male, heterosexual, 45 years, living with HIV for 2 years)
Participants described their view of living free from HIV as relief from tensions or burdens
in their social relationships–with their families and partners. These responses are a reminder
that living with HIV, is a deeply social experience. The physiological impact is only one aspect.
As is evident in the quotations above, HIV that is well managed with ART presents few physi-
cal burdens and minimal interruptions to life for many people. The burden of HIV comes
from its social impact. As such, the definition of a cure provided by participants was attuned to
the social and relational aspects of HIV more than the physical.
A cure as relief from the burden of stigma
The impact of HIV-related stigma was implicit (and, at times explicit) in most participants’
responses to a question in how a cure for HIV would change their lives. For some, being cured
of HIV–which was defined by most participants as no longer being identified as HIV positive–
would alleviate the burden of stigma that comes with being seen by others as potentially ‘infec-
tious’, as one participant explained:
[A cure for HIV] would remove that sense of being, as it were, infectious or toxic to other
people . . .You don’t have that kind of stigma. The issue of disclosing that you’re positive,
sort of, goes out of the window. And, you know, one is left in the situation where it would
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have been if you’d never had this illness in the sense of you’ve got to contend with whatever
life throws at you in terms of aging and other circumstances, but you no longer have that
stigmatized disease.
(Male, gay, 62, living with HIV for 21 years)
Look [a cure] would change my life because I wouldn’t have to be so careful about every-
thing that’s. . . yeah look, the other thing is I am not open [about HIV status] with people;
only close people I tell, you know. It’s that constant fear of people–because there’s a lot of
misunderstanding out there in the public . . . Yeah, and I suppose there’s always a fear
that you can get painted with a brush because of that lack of understanding–that probably
would be the main thing. I mean outside the obvious not having to take a pill a day or get-
ting worried if you missed one of your medications doses–that’s an inconvenience more
than anything else, but yeah, lifestyle, the fear of passing it on–and sexually transmitted
or something like that it would be a lot of weight off your shoulders. [Is that something
you’re worried about quite often?] Yes, I am . . . I am married. My wife [and I], we always
use condoms, but it would be nice not have to do that, and yeah, the other side of it would
be that even immediate family don’t know. If they come and stay over, I am hiding all the
meds and things like that. Just those two factors would be. . . a relief that’s off your
shoulders.
(Male, heterosexual, 45, living with HIV for 2 years)
Participants described this burden of stigma in terms similar to the persistent low-level anx-
iety illustrated above: stigma was experienced as a daily awareness of HIV that demanded
some form of emotional management to cope with negative feelings. As one participant said:
I think it’s 25 years that I’ve had HIV. I think I’ve developed lots and lots and lots of com-
pensatory and defensive mechanisms about the fact of living with HIV. And that’s a lot to
do with, I don’t know, developing resilience or realising resilience, or dealing with internal-
ised stigma or dealing with the shame from, you know, not keeping myself negative, and I
had all the lessons and choices and consequences that I’ve made. And there’s something
that I kind of underestimated about that continual low-level burden of maintaining that
kind of equilibrium around that sort of stuff. And I don’t know whether cure would amelio-
rate that or not; but if it did, I think that would be a fine thing. Because, although I work in
the sector and stuff, I don’t spend a lot of time talking about this. That’s one of my compen-
satory mechanisms. But sitting here talking a lot about it. I’m just kind of conscious that it
is an all-pervasive kind of burden that, but even if it’s to be ignored it takes up energy to
ignore it.
(Male, gay, 54, living with HIV for 20+ years)
As noted previously, the negative impact of living with HIV for many people whose HIV is
well managed by ART is social more than physical. This was most apparent when participants
spoke about the impact of HIV-related stigma. As can be seen in the quotations above, partici-
pants’ responses were powerful illustrations of the ways in which stigma shapes the everyday
lives of many PLHIV–some people continually check or modify their emotional responses to
internal feelings of shame or stigma, while others are vigilant about what friends and family
see or know. Again, these findings suggest that participants’ understanding of a cure incorpo-
rates the social aspects of living with HIV.
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Discussion
This paper adds further dimensions to existing research on the expectations for HIV cure
research held by PLHIV [13, 29, 30] by exploring the significance and understanding among
Australian PLHIV of the potential impact a cure might have on their everyday lives. In par-
ticular, these findings explicate how a cure for HIV is thought to improve the lives of PLHIV
who are already in good health due to routine access to ART. For participants in this study,
living with HIV brought a level of daily anxiety about social and relational complexities,
stigma, and sustaining good health into the future. ART did not fully relieve these anxieties,
with many participants describing experiences of consistently ‘looking over their shoulders’
to check they were okay. This form of vigilance, particularly about future ill-health or the
impact of HIV-related stigma, is an ongoing part of the experience of living with HIV for
many people that has been documented in various other studies [31, 32]. Even if such worry
is low level, it can be constant and wearing, negatively affecting an individual’s overall qual-
ity of life [33, 34]. A similar phenomenon in cancer is referred to by the term ‘fear of recur-
rence’ [35]. However, one important difference between HIV and cancer is disease
transmissibility, which adds a higher level of social complexity and contributes to the stigma
PLHIV experience.
The potential for HIV stigma to be relieved by biomedical treatment, including a cure for
HIV, has been explored elsewhere [30, 36]. These studies have concluded that HIV-related
stigma is complex and layered by other forms of discrimination, including homophobia and
discrimination against injecting drug users and sex workers [30]. The way HIV is perceived
in the social world is a product of social, political and historical factors, as much as it is the
biological nature of the virus. A cure for HIV would obviously be a major factor shaping
social understanding and attitudes toward HIV, but it would not be the only factor [37].
ART and viral suppression already mean that HIV is, for those who have access, a manage-
able chronic condition rather than a terminal illness. It also means HIV is sexually untrans-
mittable (undetectable = untransmittable, U = U) [3]. Despite this, HIV-related stigma
endures in ways that have not entirely been changed by ART or U = U [37]. This was evident
in this study, as participants described being burdened by fears of onward HIV transmission
or negative social reactions. Given this, a biomedical cure is unlikely to mean HIV is no lon-
ger a stigmatised condition. However elimination of the virus from the body may relieve the
everyday impact of stigma. PLHIV would no longer have to live long-term with the fear,
worry and vigilance that was described by participants in this study. Participants expressed
uncertainty that sustained virological suppression or remission would be sufficient to
achieve this, although it would be welcomed as an important advance on existing treatment.
Similar conclusions have been drawn in other studies, which have shown that PLHIV want
certainty that the virus will not return before they consider themselves cured, as they mis-
trust virologic suppression to be sustained long term [9, 38, 39]. In this study, being cured of
HIV was defined by participants as being definitively virus free–complete elimination of
HIV from the body.
There has been much discussion among researchers working in the HIV cure field about
the ethics of using HIV cure terminology to describe research for which a likely outcome is
therapeutic interventions to achieve sustained medication-free suppression of HIV (or
remission), rather than elimination of HIV from the body [16, 18, 40]. Many PLHIV may be
likely to participate in research aimed toward developing therapies for medication-free viral
suppression due to the benefits of reduced reliance on everyday ART [8]. However, the aspi-
ration for HIV cure research held by participants in this study was the longer-term goal of
being HIV free. There is an ethical need to consider the ways in which HIV cure research is
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presented and discussed in forums such as media reporting, including the terminology used
to describe trials for which elimination of HIV from the body is unlikely to be achieved in
the shorter term [15].
Use of specific terminology in public and media reporting on HIV cure research will also
help to ensure community expectations for HIV cure research are realistic. This is important
to sustain levels of public trust and engagement in HIV science over the longer term. The
tension with this, however, is that the aspiration and language of ‘cure’ is powerful and cap-
tures attention and imagination that attracts funding and support for research. There is a
challenge in maintaining energy and focus on the longer-term goal of achieving elimination
of HIV from the body while also ensuring affected communities are presented with realistic
expectations of shorter-term research outcomes. Active involvement of both researchers and
community advocates in the design and delivery of public messages about HIV cure research
will help to ensure messages are created with due consideration to how they may be received
by affected communities and PLHIV. In this respect, fulfilling the global principle of ensur-
ing greater and meaningful involvement of PLHIV (GIPA/MIPA) in research is politically
and ethically important, but also plays a role in managing quality and accuracy of research
output [41].
The findings of this study also suggest there may be value in further research to explore
acceptability among PLHIV of therapeutic interventions designed explicitly to achieve sus-
tained, medication-free, viral suppression or remission. If PLHIV are seeking certainty with
respect to viral suppression in order to allay anxiety about onward transmission and future ill
health, there will need to be a high level of confidence that any new therapeutic interventions
will provide this level of certainty.
These findings build on existing research about the reasons why PLHIV might be willing to
take risks with their health to volunteer for HIV cure clinical trials. Various studies have
shown that PLHIV in many parts of the world have expressed willingness to be involved in
HIV cure research for social and altruistic motivations, including a desire to give back to com-
munities that have supported them [8, 11, 42]. Some PLHIV already are involved in early
stages of HIV research towards a cure [11, 14, 43]. There is a strong culture of support for
research in all sectors of the HIV community in Australia and internationally [44, 45]. This
suggests that many PLHIV are conversant with research, its processes, its strengths and limita-
tions, and are familiar with many long-serving researchers in the HIV field. However, HIV
cure research is different from other HIV-related research in that it asks PLHIV to take a risk
with their current state of good health to be part of early stage research and, potentially,
threaten the gains they have achieved in securing that health for no likely clinical benefit. For
example, many HIV cure-focused clinical trials involved analytic treatment interruptions, dur-
ing which participants are required to suspend ART for a period of time, and which may
increase the chance of onward HIV transmission through sexual contact–something inter-
viewees in this study were clearly concerned about [7, 46–48]. However, findings from this
study show that, despite the effectiveness of modern ART, a cure for HIV would have a signifi-
cant psychological and social impact on the everyday lives of PLHIV. PLHIV may consider the
risks of participation in an HIV cure-related clinical trial through this lens. Even among
PLHIV who are physically healthy, there may be vulnerabilities and stressors associated with
living with HIV that might reduce people’s perception of their wellbeing when weighing up
risks [40]. In addition, living with everyday stressors and vulnerabilities associated with HIV
may be what makes participation in research toward a possible cure meaningful and significant
for PLHIV in ways that are difficult to assess objectively [42]. Again, this speaks to the impor-
tance of including PLHIV on clinical trial research teams so perspectives gained through the
experience of living with HIV can inform these trials.
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Limitations
There are limitations to this study to consider. First, being located in Australia, all participants
in this study had access to publicly funded healthcare and subsidised ART. This may not the
case in many other settings. The relevance of a cure for HIV, and the significance of sustained,
medication-free, viral suppression, might be different for PLHIV who have no or less reliable
access to ART. The sample size was also small and lacked ethnic or cultural diversity, so should
not be considered reflective of the perspectives of all PLHIV.
Conclusion
Despite HIV being a manageable condition for people with access to ART, a cure that elimi-
nates HIV from the body would fundamentally change the lives of many PLHIV. As shown in
this study, the impact of HIV affects an individual’s social, psychological and emotional life,
extending far beyond physical health alone. The cure most desired by PLHIV is one that can
relieve or reverse these negative impacts [40]. This is important to consider in the context of
the ethics of HIV cure research. Research that considers the lived experiences and perspectives
of PLHIV is necessary to determine acceptability of HIV cure research and trial participation
as well as likely outcomes from such research. The hopes and expectations that PLHIV and
affected communities hold for HIV cure research may not align with the possible shorter-term
outcomes of current cure research. This is so because the more likely shorter-term outcome
from research toward a cure for HIV is sustained, medication-free, viral suppression (or remis-
sion), which, while significant, is very likely to be considered by many PLHIV as an extension
of treatment rather than a cure [40].
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